Immunotech Laboratories, Inc.
Built from real-time financials and updated daily. For a full Analyst Grade with bull/bear case, price targets, and qualitative risk analysis, generate a IMMB research report →
Companywww.immunotechlab.com
Immunotech Laboratories, Inc. develops and commercializes proprietary proteins for use in treating human immunodeficiency virus (HIV), acquired immune deficiency syndrome (AIDS), hepatitis, and other immuno-related disorders. Its flagship compound is ITV-1 (immune therapeutic vaccine), a suspension of irreversible pepsin fraction that is used in the treatment of HIV/AIDS and Hepatitis C, as well as to modulate the immune system.
- CEO
- Harry H. Zhabilov Jr. McS
- IPO
- 2022
- Employees
- 4
- HQ
- Monrovia, US
Price Chart
Valuation
- Market Cap
- $114.99K
- P/E
- -0.23
- P/S
- 0.00
- P/B
- 0.02
- EV/EBITDA
- -5.55
- Div Yield
- 0.00%
Profitability
- Gross Margin
- 0.00%
- Op Margin
- 0.00%
- Net Margin
- 0.00%
- ROE
- -9.01%
- ROIC
- -6.52%
Growth & Income
- Revenue
- $0 · 0.00%
- Net Income
- $-493,029 · 0.00%
- EPS
- $-0.00 · 0.00%
- Op Income
- $-470,361
- FCF YoY
- 0.00%
Performance & Tape
- 52W High
- $0.00
- 52W Low
- $0.00
- 50D MA
- $0.00
- 200D MA
- $0.00
- Beta
- -77.02
- Avg Volume
- 3.65K
Get TickerSpark's AI analysis on IMMB
Pro members can request AI-generated analysis on any ticker — technical setup, analyst consensus, earnings watch, insider pulse, financial health, and peer context. Ready in about a minute.
Get Pro Access →30-day money-back guarantee · cancel anytime
Our IMMB Coverage
We haven't published any research on IMMB yet
For a full analyst-grade research report — grades, price targets, full financials, chart analysis — generate one on demand.
Generate IMMB Report →